RTW Investments LP reduced its holdings in Novavax, Inc. (NASDAQ:NVAX) by 3.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,644,346 shares of the biopharmaceutical company’s stock after selling 82,158 shares during the quarter. RTW Investments LP’s holdings in Novavax were worth $3,543,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. New York State Common Retirement Fund increased its stake in Novavax by 13.1% in the 1st quarter. New York State Common Retirement Fund now owns 331,928 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 38,480 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Novavax by 9.0% in the 1st quarter. Wells Fargo & Company MN now owns 507,975 shares of the biopharmaceutical company’s stock worth $1,066,000 after purchasing an additional 41,741 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Novavax by 15.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 339,189 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 46,300 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Novavax in the 1st quarter worth about $119,000. Finally, Rhumbline Advisers boosted its holdings in shares of Novavax by 22.8% in the 2nd quarter. Rhumbline Advisers now owns 375,833 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 69,675 shares in the last quarter. Institutional investors and hedge funds own 43.99% of the company’s stock.
A number of research firms have recently issued reports on NVAX. Zacks Investment Research cut Novavax from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. BidaskClub cut Novavax from a “sell” rating to a “strong sell” rating in a report on Thursday, June 28th. Finally, ValuEngine upgraded Novavax from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. Novavax currently has an average rating of “Hold” and a consensus target price of $3.51.
NVAX opened at $1.48 on Friday. Novavax, Inc. has a 12-month low of $0.96 and a 12-month high of $2.75. The company has a debt-to-equity ratio of -3.63, a current ratio of 4.52 and a quick ratio of 4.52. The stock has a market capitalization of $581.54 million, a PE ratio of -2.35 and a beta of 2.62.
Novavax (NASDAQ:NVAX) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $10.02 million. The company’s revenue was up 61.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.16) earnings per share. equities research analysts expect that Novavax, Inc. will post -0.54 EPS for the current year.
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Recommended Story: Discover Your Risk Tolerance
Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX).
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.